Memorial Sloan Kettering Cancer Center

Topical ruxolitinib cream significantly reduced skin manifestations caused by cutaneous graft-versus-host disease compared with vehicle cream, results from a randomized phase 2 study showed.

Researchers at several institutions collaborated to develop the first computational model that predicts prognosis for patients newly diagnosed with multiple myeloma based on tumor genomics and treatments.

More than one in five people with cancer did not receive clinician-recommended care due to prior authorization requirements, according to study results.

In a special scientific session on race and science at ASH Annual Meeting an Exposition, Saad Z. Usmani, MD, MBA, FACP, FRCP, examined clinical trial inclusion from an investigator’s perspective.

SAN DIEGO — Subcutaneous time-limited mosunetuzumab exhibited “highly encouraging efficacy” among patients with newly diagnosed high-burden follicular lymphoma, according to researchers.

Several hematologists will be honored during this year’s ASH Annual Meeting, scheduled for Dec. 9-12 in San Diego.

For individuals diagnosed with cancer, guideline-concordant exercise reduced all-cause mortality by 25% compared with patients with cancer who did not exercise, study results published in Journal of Clinical Oncology showed.

Precision oncology therapies requiring biomarker testing comprised 43% of all FDA oncology drug approvals between 1998 and 2022, study results published in Cancer Discovery showed.

Sandra D’Angelo, MD, discussed initial phase 1A/1B data from a clinical trial on the efficacy and safety of BI-907828, a MDM2 inhibitor, in patients with liposarcoma presented at the Connective Tissue Oncology Society Annual Meeting.

A CDK9 inhibitor, known as KB-0742, showed preliminary evidence of clinical activity in patients with various sarcomas, according to a study presented at the Connective Tissue Oncology Society Annual Meeting.